Mitochondria-targeted tetraoxanes initiate lipid peroxidation to drive ferroptosis and tumor suppression.

Mitochondria-targeted tetraoxanes WMK-1/2 induce ferroptosis independently of GPX4, suppressing tumors in multiple cancer models.

• Why it matters: Inducing ferroptosis effectively in vivo remains challenging, especially beyond conventional GPX4 or FSP1 targeting, limiting therapeutic options for various cancers.
• What they did: Researchers designed MILPOs, specifically WMK-1/2, which localize to mitochondria, generate lipid peroxidation, and trigger a "mito-ferroptosis" pathway that bypasses GPX4 inhibition, tested in cancer models.
• The result: WMK-1/2 exhibit significant tumor suppression by inducing ferroptosis, are bioavailable, and enhance immune-checkpoint blockade effects, offering a new protein-independent cancer therapy approach.